Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened Kidney Function.

Pharmacology - 1 Jan 2021

Kwiatkowski Jacek, Kuliszkiewicz-Janus Małgorzata, Rymer Weronika, Jaźwiec Bożena, Małecki Rafał

Abstract excerpt

BACKGROUND AND PURPOSE: When choosing a cytoreduction method for patients suffering from essential thrombocythemia (ET), it is important to know the safety profile of the medicine used. Few articles have been published about the effects of hydroxycarbamide (hydroxyurea, HU) and anagrelide (ANA) on renal function in ET patients. This study is the largest analysis of nephrotoxicity of cytoreductive drugs used in ET...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calreticulin
Share to Creatinine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxyurea

Share to Janus Kinase 2

Share to Kidney Diseases

Share to Platelet Aggregation Inhibitors

Share to Quinazolines

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 33691325
DOI: 10.1159/000513377

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened Kidney Function.PMID 33691325Read ↗

Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.Semantic proximity Read ↗

Essential thrombocythemia treatment algorithm 2018.Semantic proximity Read ↗

Clinical features and current treatment status of essential thrombocythemia in older adults: a multicenter real-world study in China.Semantic proximity Read ↗

Anagrelide and Mutational Status in Essential Thrombocythemia.Semantic proximity Read ↗

Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia.Semantic proximity Read ↗

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study.Semantic proximity Read ↗

Significant heterogeneity in management of calreticulin-mutated essential thrombocythemia and its progression to myelofibrosis: results of a national survey.Semantic proximity Read ↗

A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia.Semantic proximity Read ↗

Therapeutic plasma exchange experience in internal medicine clinics: a retrospective review of 1,048 proceduresSemantic proximity Read ↗

JAK2 or CALR Mutations Status and Bone Marrow Histology in Patients with Essential Thrombocythemia in ChineseSemantic proximity Read ↗

The advantages and risks of ruxolitinib for the treatment of polycythemia vera.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.